Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.49 |
| ▸ | PPARG | P37231 | 8/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 6/20 | 0.47 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PTGES | O14684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1122793 | 0.95 | L3MBTL1 (0.47) | PPARAPPARGSLC2A1SLC2A4L3MBTL1 | |
| SCHEMBL1123269 | 0.93 | L3MBTL1 (0.50) | PPARAPPARGL3MBTL1PTGESALOX5 | |
| SCHEMBL1122873 | 0.92 | SLC2A1 (0.45) | PPARAPPARGSLC2A1SLC2A4L3MBTL1 | |
| SCHEMBL1122770 | 0.91 | SLC2A1 (0.46) | PPARAPPARGSLC2A1SLC2A4L3MBTL1 | |
| SCHEMBL1123219 | 0.87 | CYSLTR2 (0.45) | PPARAPPARGSLC2A1SLC2A4L3MBTL1 | |
| SCHEMBL1123226 | 0.86 | L3MBTL1 (0.43) | PPARAPPARGSLC2A1SLC2A4L3MBTL1 | |
| SCHEMBL1123108 | 0.86 | L3MBTL1 (0.45) | PPARAPPARGSLC2A1SLC2A4L3MBTL1 | |
| SCHEMBL1122802 | 0.84 | L3MBTL1 (0.47) | PPARAPPARGL3MBTL1PTGESALOX5 | |
| SCHEMBL1123013 | 0.83 | FFAR1 (0.58) | SLC2A1SLC2A4PTGESALOX5LTC4S | |
| SCHEMBL5720728 | 0.82 | CYSLTR2 (0.45) | PPARAPPARGSLC2A1SLC2A4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644321-B1 | NEW BENZAMIDES AS PPATY MODULATORS | S A L V A T LAB SA (ES) | 2011-02-09 | — | — | EP | disclosed |
| US-20060160894-A1 | Benzamides as ppar modulators | LABORATORIOS S.A.L.V.A.T.,S.A. (ES) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160894-A1 | Benzamides as ppar modulators | PPARD, PPARA, PPARG | PPARA 2/4885PPARG 3/4885SLC2A1 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.